6.63
price up icon1.69%   +0.11
 
loading
Axogen Inc. stock is currently priced at $6.63, with a 24-hour trading volume of 418.16K. It has seen a +1.69% increased in the last 24 hours and a -12.19% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $6.62 pivot point. If it approaches the $6.77 resistance level, significant changes may occur.
Previous Close:
$6.52
Open:
$6.53
24h Volume:
418.16K
Market Cap:
$289.65M
Revenue:
$159.01M
Net Income/Loss:
$-21.72M
P/E Ratio:
-11.84
EPS:
-0.56
Net Cash Flow:
$-20.63M
1W Performance:
+2.00%
1M Performance:
-12.19%
6M Performance:
+80.16%
1Y Performance:
-27.78%
1D Range:
Value
$6.4301
$6.70
52W Range:
Value
$3.45
$10.83

Axogen Inc. Stock (AXGN) Company Profile

Name
Name
Axogen Inc.
Name
Phone
386-462-6800
Name
Address
13631 Progress Boulevard, Suite 400, Alachua, FL
Name
Employee
184
Name
Twitter
@AxoGen
Name
Next Earnings Date
2024-05-07
Name
Latest SEC Filings
Name
AXGN's Discussions on Twitter

Axogen Inc. Stock (AXGN) Upgrades & Downgrades

Date Action Analyst Rating Change
Nov-11-22 Resumed Jefferies Buy
May-09-22 Upgrade Canaccord Genuity Hold → Buy
Mar-11-22 Resumed Cantor Fitzgerald Overweight
Oct-23-20 Initiated Guggenheim Buy
Jun-16-20 Resumed Cantor Fitzgerald Overweight
May-07-20 Downgrade Canaccord Genuity Buy → Hold
Apr-02-20 Downgrade BTIG Research Buy → Neutral
Aug-07-19 Downgrade William Blair Outperform → Mkt Perform
Jul-12-19 Initiated Canaccord Genuity Buy
Mar-02-18 Reiterated Lake Street Buy
Jan-05-18 Resumed Cantor Fitzgerald Overweight
Nov-30-17 Initiated Jefferies Buy
Nov-21-17 Reiterated Lake Street Buy
Jul-31-17 Initiated Leerink Partners Outperform
Jun-30-17 Initiated Cantor Fitzgerald Overweight
Mar-06-17 Initiated ROTH Capital Buy
Nov-22-16 Upgrade Lake Street Hold → Buy
Nov-07-16 Reiterated Wedbush Outperform
Nov-03-16 Downgrade Lake Street Buy → Hold
Aug-04-16 Reiterated Wedbush Outperform
May-14-14 Initiated Dawson James Buy
Oct-31-13 Reiterated Ladenburg Thalmann Buy
View All

Axogen Inc. Stock (AXGN) Financials Data

Axogen Inc. (AXGN) Revenue 2024

AXGN reported a revenue (TTM) of $159.01 million for the quarter ending December 31, 2023, a +14.74% rise year-over-year.
loading

Axogen Inc. (AXGN) Net Income 2024

AXGN net income (TTM) was -$21.72 million for the quarter ending December 31, 2023, a +24.98% increase year-over-year.
loading

Axogen Inc. (AXGN) Cash Flow 2024

AXGN recorded a free cash flow (TTM) of -$20.63 million for the quarter ending December 31, 2023, a +44.71% increase year-over-year.
loading

Axogen Inc. (AXGN) Earnings per Share 2024

AXGN earnings per share (TTM) was -$0.52 for the quarter ending December 31, 2023, a +23.53% growth year-over-year.
loading

Axogen Inc. Stock (AXGN) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Zaderej Karen L.
CEO
Mar 21 '24
Sale
7.68
39,280
301,670
1,124,565
Scopelianos Angelo
Chief R&D Officer
Mar 21 '24
Sale
7.68
6,881
52,846
52,999
Donovan Michael Patrick
VP Operations
Mar 21 '24
Sale
7.68
6,033
46,333
37,992
DeVinney Erick Wayne
Chief Innovation Officer
Mar 21 '24
Sale
7.68
4,578
35,159
165,661
Zaderej Karen L.
CEO
Mar 16 '24
Option Exercise
0.00
110,322
0
1,157,593
DeVinney Erick Wayne
Chief Innovation Officer
Mar 16 '24
Option Exercise
0.00
18,675
0
180,615
Scopelianos Angelo
Chief R&D Officer
Mar 16 '24
Option Exercise
0.00
25,406
0
58,250
Donovan Michael Patrick
VP Operations
Mar 16 '24
Option Exercise
0.00
24,575
0
58,846
Donovan Michael Patrick
VP Operations
Mar 07 '24
Sale
8.81
36,310
319,891
35,708
Freitag Gregory Gene
Director
Mar 07 '24
Sale
9.00
25,000
225,000
271,594
AxoGen, Inc. develops and markets surgical solutions for peripheral nerve injuries. The company's surgical solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its solutions also comprise Avive Soft Tissue Membrane, a minimally processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues and modulate inflammation in the surgical bed. In addition, the company offers AcroVal neurosensory and motor testing system, which consists of AcroGrip for use in hand grip strength measurement; AcroPinch for measuring pinch strength; and Pressure-Specified Sensory Device, a somatosensory evaluation and measurement device. Further, it provides AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals in the United States, Canada, the United Kingdom and other European countries, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.
medical_devices PHG
$21.07
price up icon 1.69%
medical_devices STE
$203.90
price up icon 1.17%
$309.02
price down icon 0.48%
medical_devices ZBH
$119.35
price down icon 0.33%
$124.34
price down icon 9.91%
medical_devices EW
$86.43
price down icon 1.80%
Cap:     |  Volume (24h):